Shinji Yamazaki
Simcyp (United Kingdom)(GB)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Computational Drug Discovery Methods, Structural Engineering and Vibration Analysis, Structural Load-Bearing Analysis, Drug Transport and Resistance Mechanisms
Most-Cited Works
- → Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)(2011)909 cited
- → An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms(2007)749 cited
- → Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma(2007)643 cited
- → Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3(2008)623 cited
- → PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models(2015)458 cited
- → Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective